In atopic and irritant dermatitis models, topical BCP suppresses keratinocyte interleukin-4 (IL-4)–driven thymic stromal lymphopoietin (TSLP) signaling and improves lesion severity [30]. This evidence concerns the gene IL4 and irritant dermatitis.